Skip to main content Skip to search Skip to main navigation

MHRA: UK and Canada – mutual recognition of GMP and batch testing certificates

On 5 January 2021, the UK MHRA published a joint statement by the UK and Canada, which applies on an interim basis and is intended to avoid trade disruptions as a result of the Brexit. 

Thus, GMP certificates and batch inspection certificates are to be mutually recognized to avoid re-controls after importation.  

Until 31 December 2020, trade between the UK and Canada was regulated by the CETA agreement. With Brexit coming into force, the UK's participation has ended.    

Unlike the EU-UK trade agreement, the UK-Canada agreement is more comprehensive, as it also regulates batch testing. In contrast, products imported into the EU from the UK have to be retested. 

The interim agreement between Canada and the UK is to be followed by a more extensive trade agreement after ratification. 


Source:

MHRA: Common Statement Canada-United Kingdom (as of 1 January 2021)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
News: Artificial Intelligence

Annex 22: Results of the EMA Workshop

On 30 June, the EMA’s Annex 22 Working Group discussed the future scope of the annex with AI experts and representatives of the pharmaceutical industry (as previously reported).
Read more
Previous
Next